Do Hedge Funds Love Bristol Myers Squibb Company (BMY) As Much As Buffett Does?Insider Monkey • 11/24/20
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 11/24/20
Schrödinger in drug development agreement with Bristol Myers worth up to $2.7 billion in milestone and royalty paymentsMarket Watch • 11/23/20
Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers SquibbBusiness Wire • 11/23/20
Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Wolfe Research Healthcare Conference (Transcript)Seeking Alpha • 11/18/20
Bristol-Myers Squibb Continues On Its Path To Becoming The Next Quarter Trillion-Dollar CompanySeeking Alpha • 11/18/20
Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 yearsBusiness Insider • 11/18/20
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company's Leading Cardiovascular FranchiseBusiness Wire • 11/17/20
AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarterBusiness Insider • 11/17/20
Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to MarketBusiness Wire • 11/17/20
The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical TrialsBusiness Wire • 11/17/20